Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccines - A prospective multi-center study.
Phuensan P, Sirimongkolkasem J, Tantawichien T, Phannajit J, Kerr SJ, Hansasuta P, Chantharit P, Wongsa A, Fuengfoo P, Chittinandana A, Vareesangthip K, Chayakulkeeree M, Jangsirikul S, Schmidt A, Wanvimonsuk K, Winichakoon P, Kajeekul R, Prayoonwiwat W, Rerknimitr R.
Phuensan P, et al. Among authors: wongsa a.
Heliyon. 2023 Dec 3;10(1):e23246. doi: 10.1016/j.heliyon.2023.e23246. eCollection 2024 Jan 15.
Heliyon. 2023.
PMID: 38163241
Free PMC article.